Clinical and Basic Science Research in Sexual Medicine Must Rely, in Part, on Pharmaceutical Funding?

Journal of Sexual Medicine

Volumn 7, Issue 7, 2010, Pages 2331-2337

  Jannini, Emmanuele A ^a   Eardley, Ian ^b   Sand, Michael ^c   Hackett, Geoffrey ^d  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Funding; Grant; Industry; Research

Indexed keywords

APPLIED RESEARCH; ARTICLE; BASIC RESEARCH; CLINICAL RESEARCH; CONFLICT OF INTEREST; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE CLASSIFICATION; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; FEMALE SEXUAL DYSFUNCTION; FUNDING; HUMAN; PREMATURE EJACULATION; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; SCIENTIFIC MISCONDUCT; SEXOLOGY;

EID: 77955162898     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01898.x     Document Type: Article

References (33)

1. Lo B. Serving two masters-Conflicts of interest in academic medicine. N Engl J Med 2010, 362:669-71.
2. Lo B, Field MJ. Conflict of interest in medical research, education, and practice 2009, Washington, DC, National Academic Press
3. Neill US. Publish or perish, but at what cost? J Clin Invest 2008, 118:2368.
4. http://www.equator-network.org, Equator Network Web site, Available at: (accessed May 18, 2010)
5. Moynihan R. The making of a disease: Female sexual dysfunction. BMJ 2003, 326:45-7.
6. Binik YM, Meana M. The future of sex therapy: Specialization or marginalization? Arch Sex Behav 2009, 38:1016-27.
7. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA 1999, 281:537-44.
8. Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, IV-TR edition, Arlington, Va, American Psychiatric Association
9. Waldinger MD. Not medical solutions, but overmedicalization by pharmaceutical company policies endanger both sexological care, science, and sexual medicine. A commentary. J Sex Marital Ther 2008, 34:179-83.
10. Segraves R, Balon R, Clayton A. Proposal for changes in diagnostic criteria for sexual dysfunctions. J Sex Med 2007, 4:567-80.
11. Waldinger MD. Premature ejaculation: Different pathophysiologies and etiologies determine its treatment. J Sex Marital Ther 2008, 34:1-13.
12. Waldinger MD. Recent advances in the classification, neurobiology and treatment of premature ejaculation. Adv Psychosom Med 2008, 29:50-69.
13. Goldstein I. Regarding Waldinger and Schweitzer's " premature ejaculation and pharmaceutical company-based medicine: The dapoxetine case." J Sex Med 2008, 5:965.
14. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: A systematic review. JAMA 2003, 289:454-65.
15. Nicolosi A, Laumann EO, Glasser DB, Moreira ED, Paik A, Gingell C. Sexual behavior and sexual dysfunctions after age 40: The global study of sexual attitudes and behaviors. Urology 2004, 64:991-7.
16. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004, 20:607-17.
17. Fisher WA, Rosen RC, Eardley I, Sand M, Goldstein I. Sexual experience of female partners of men with erectile dysfunction: The female experience of men's attitudes to life events and sexuality (FEMALES) study. J Sex Med 2005, 2:675-84.
18. Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J. The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: Prevalence, comorbidities, and professional help-seeking. Eur Urol 2007, 51:816-23. discussion 824
19. Leiblum SR, Koochaki PE, Rodenberg CA, Barton IP, Rosen RC. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause 2006, 13:46-56.
20. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: Prevalence and correlates. Obstet Gynecol 2008, 112:970-8.
21. Arnow BA, Millheiser L, Garrett A, Lake Polan M, Glover GH, Hill KR, Lightbody A, Watson C, Banner L, Smart T, Buchanan T, Desmond JE. Women with hypoactive sexual desire disorder compared to normal females: A functional magnetic resonance imaging study. Neuroscience 2009, 158:484-502.
22. Corona G, Jannini EA, Maggi M. Inventories for male and female sexual dysfunctions. Int J Impot Res 2006, 18:236-50.
23. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003, 22:151-85.
24. Duvall DG. Conflict of interest or ideological divide: The need for ongoing collaboration between physicians and industry. Curr Med Res Opin 2006, 22:1807-12.
25. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002, 360:1623-30.
26. Blumenthal D, Campbell EG, Anderson MS, Causino N, Louis KS. Withholding research results in academic life science. Evidence from a national survey of faculty. JAMA 1997, 277:1224-8.
27. Lexchin JR. Implications of pharmaceutical industry funding on clinical research. Ann Pharmacother 2005, 39:194-7.
28. Angell M. Industry-sponsored clinical research: A broken system. JAMA 2008, 300:1069-71.
29. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation. JAMA 2008, 299:1800-12.
30. Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: A case study based on documents from rofecoxib litigation. JAMA 2008, 299:1813-7.
31. Smith R. Beyond conflict of interest. Transparency is the key. BMJ 1998, 317:291-2.
32. Sotelo J. Regulation of clinical research sponsored by pharmaceutical companies: A proposal. PLoS Med 2006, 3:e306.
33. Doucet M, Sismondo S. Evaluating solutions to sponsorship bias. J Med Ethics 2008, 34:627-30.